Medtronic has reported three milestones in the US, expanding access to its MiniMed 780G insulin delivery system for individuals with type 1 diabetes (T1D) and insulin-requiring type 2 diabetes (T2D).
These include the US Food and Drug Administration (FDA) clearance to use the MiniMed 780G system with ultra-rapid-acting insulins, as well as clearance of the system with Instinct for insulin-requiring T2D.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company also announced Medicare access to the MiniMed 780G system paired with the Instinct sensor from Abbott.
Beneficiaries of Medicare and Medicare Advantage can now obtain the system combined with the Instinct sensor, which is compact, slim, can be worn discreetly, and provides up to 15 days of continuous use.
This expands choice alongside Simplera Sync and Guardian 4 sensors for Medicare users. Medtronic Diabetes is collaborating with distributor partners for prompt shipment and support for eligible customers.
The FDA cleared the use of ultra-rapid-acting insulins Fiasp and Lyumjev with the MiniMed 780G system, offering enhanced flexibility and therapy personalisation for people with T1D or insulin-requiring T2D.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdditionally, it cleared the MiniMed 780G pump as an alternate controller enabled (ACE) device for insulin-requiring T2D and the SmartGuard algorithm as an interoperable automated glycaemic controller (iAGC). This allows integration with Abbott’s Instinct sensor.
The expanded approvals mean individuals can now order the MiniMed 780G system with Instinct, Guardian 4 or Simplera Sync sensors for broader personalisation in diabetes management.
Medtronic executive vice-president and president Que Dallara said. “These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition.
“By broadening sensor and insulin options for the MiniMed 780G system, we’re empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier.”
In January 2026, Medtronic received 510(k) clearance from the FDA for its MiniMed Go Smart MDI system, a solution aimed at supporting individuals with insulin-requiring T1D and T2D.
